All Posts

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

What Are We Looking At: There are six PDUFA dates in April 2023 for small to large cap biotech. However, a majority of these upcoming...

Access the Big Mover Report with detailed info on the biggest clinical readouts this quarter: Big Mover table

Summary: We previously analyzed the 36 life science hedge funds to determine which smid-cap biopharmas were in the most Top 20s See our...

Summary:

We've reached the end of Q1. April has a lot of events happening including 8 PDUFA's, the AACR cancer meeting, and some other company...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Doing diligence on clinical trial readouts with our BPIQ team Reminds me of some important considerations for the likelihood of success: ⇨Prior data for the on-test drug ⇨⇨Same endpoints? ⇨⇨Not available? Then prior trial data for other drugs with the same MOA ⇨Trial design ⇨⇨ Are the characteristics of patients allowed into the trial the same? ⇨⇨⇨ Especially the severity of the disease ⇨⇨How many patients? ⇨⇨How many clinical sites? & Likelihood of stock move ⇨Market reactio

Summary:

Last updated 4/10/23 Summary: AACR is only a few weeks away - the conferences starts April 14th, also when abstract text is released What...